Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Viatris

VTRS

17.1550.15% ( -0.025 )

Trading: Sep 23, 12:17:33 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields
benzinga_article·5 hours ago
VTRS-0.15%CVS-1.37%
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Pharmaceutical Business Review·Sep 17 at 09:20 AM
VTRS-0.15%
Piper Sandler maintains Neutral rating on Viatris, $13 price target
TradingView·Sep 16 at 05:31 PM
VTRS-0.15%
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
prnewswire·Sep 16 at 10:59 AM
VTRS-0.15%
Macro Signals from the Margins: How Niche Equities Are Telegraphing Market Divergence
Global Report·Sep 15 at 10:12 AM
MRVX-3.40%AVIG-0.77%
Viatris Inc. Stock Rises Wednesday, Outperforms Market
MarketWatch Automated·Sep 2 at 09:06 PM
VTRS-0.15%
Viatris Inc. Stock Falls Friday, Underperforms Market
MarketWatch Automated·Aug 28 at 09:07 PM
VTRS-0.15%
REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
London Stock Exchange·Aug 27 at 03:00 PM
VTRS-0.15%
Viatris Inc. Stock Rises Tuesday, Outperforms Market
MarketWatch Automated·Aug 25 at 09:08 PM
VTRS-0.15%
The 'Other' Bucket: Why Wall Street's Leftovers Demand a Closer Look
Global Report·Aug 25 at 11:33 AM
VERI+3.52%ROOT-4.01%
Diversified Assets in Focus: Latest Moves on AAC, Entergy and 7 Other Picks
Global Report·Aug 25 at 09:21 AM
02549-3.67%PSIX-0.30%
Viatris Inc. Stock Rises Monday, Outperforms Market
MarketWatch Automated·Aug 24 at 09:07 PM
VTRS-0.15%